Stockscreener 앱 받기
6.23
2.66%
-0.17
시간 외 거래:
6.23
전일 마감가:
$6.40
열려 있는:
$6.57
하루 거래량:
15,665
Relative Volume:
0.08
시가총액:
$380.51M
수익:
-
순이익/손실:
$-159.39M
주가수익비율:
-1.7598
EPS:
-3.5401
순현금흐름:
$-105.22M
1주 성능:
+3.83%
1개월 성능:
-15.58%
6개월 성능:
-40.67%
1년 성능:
-59.31%
1일 변동 폭
$6.165
$6.75
1주일 범위
$5.89
$6.75
52주 변동 폭
$4.77
$16.63
Abivax Adr Stock (ABVX) Company Profile
ABVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
6.23 | 380.51M | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | Laidlaw | Buy |
| 2024-05-20 | 개시 | BTIG Research | Buy |
| 2024-04-29 | 개시 | Guggenheim | Buy |
| 2024-04-29 | 개시 | Piper Sandler | Overweight |
| 2023-11-14 | 개시 | Leerink Partners | Outperform |
| 2023-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Abivax Adr 주식(ABVX)의 최신 뉴스
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - GlobeNewswire Inc.
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater
Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater
Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater
Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater
Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire
Abivax Adr (ABVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):